Gold vs. platinum-iridium tip catheter for cavotricuspid isthmus ablation: the AURUM 8 study

Aims Gold electrodes have the theoretical advantage of creating bigger lesions than platinum–iridium (Pt–Ir) electrodes. We performed a prospective randomized study to compare the clinical efficacy of standard 8 mm Pt–Ir tip catheter (control) and 8 mm gold-tip catheters in the ablation of the cavotricuspid isthmus (CTI)-dependent atrial flutter. Methods and results A total of 463 patients undergoing CTI ablation in 19 clinical centres were randomized to receive the treatment by gold-tip or control catheter. The primary endpoint was cumulative radiofrequency (RF) application duration until achieving bidirectional CTI block. It did not differ significantly for the two catheters. The gold-tip catheter was, however, associated with a higher ablation success rate (94.3 vs. 89.0%, P = 0.042) and a substantially lower incidence of char and coagulum formation (4.8 vs. 37.9%, P < 0.001), which required exchange of 1 gold-tip (0.4%) and 10 control catheters (4.6%, P = 0.005). The gold-tip catheter delivered more mean power (52 ± 12 W) than the control catheter (48 ± 13 W, P < 0.001). Both mean and maximum temperatures measured by the thermocouple integrated in the catheter tip were statistically significantly lower in the gold (mean: 53.2 ± 4.7°C, max: 68.7 ± 6.6°C) than in the control catheter (54.3 ± 5.2 and 70.2 ± 7.0°C, respectively, P < 0.05). Fluoroscopy time, procedure duration, procedural-related complications, and arrhythmia recurrence during 6 months of follow-up did not differ between the two catheters. Conclusion Owing to a higher primary ablation success rate and reduced incidence of char/coagulum formation, gold may be preferred over Pt–Ir as electrode material for 8 mm tip catheters for CTI ablation. ClinicalTrials.gov: [NCT00326001][1] ([http://clinicaltrials.gov/ct2/show/[NCT00326001][1]][2]). [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00326001&atom=%2Feuropace%2F13%2F1%2F102.atom [2]: http://clinicaltrials.gov/ct2/show/NCT00326001